What is a peptide bond in simple terms?

A peptide bond is a covalent chemical link formed when the carboxyl group of one amino acid reacts with the amino group of another, releasing a water molecule. It's the bond that joins amino acids into chains to form peptides and proteins.

Why are peptide bonds hard to deliver orally?

Proteases in the stomach and small intestine break peptide bonds efficiently, degrading most unmodified peptide compounds before they reach systemic circulation. This severely limits oral bioavailability, which is why many peptide compounds in research contexts are administered by subcutaneous injection instead.

What is the difference between a peptide and a protein?

Both are chains of amino acids linked by peptide bonds. The distinction is largely one of length — peptides are generally considered to be chains of fewer than roughly 50 amino acid residues, while proteins are longer. The boundary is not fixed and the terminology overlaps in practice.

Are synthetic peptides legal in Australia?

It depends entirely on the specific compound and its regulatory status. Peptide therapeutic goods must be entered on the Australian Register of Therapeutic Goods (ARTG) to be legally supplied. Many synthetic peptides marketed online are unapproved, and supplying them is illegal under the Therapeutic Goods Act 1989. Some clinically recognised peptide compounds may be available via prescription or the Special Access Scheme. The TGA is the authoritative source on any specific compound's status.

What makes proline unusual in a peptide chain?

Proline's side chain forms a ring that bonds back to the backbone nitrogen, which restricts rotation around the preceding peptide bond and prevents standard hydrogen bonding. This disrupts the formation of alpha-helices and beta-sheets at that position, giving proline the ability to introduce structural kinks or turns in a peptide chain.

The Peptide Bond

By Priya Nandakumar · 3 July 2026 · 7 min read

a pile of red balls with blue string on them

Somewhere around kilometre 28 of a long run last weekend, I started thinking about condensation reactions. That's probably a sign I've been in this field too long , but bear with me, because the chemistry that happens when two amino acids join hands is genuinely worth a few minutes of your attention.

The peptide bond is one of those concepts that looks deceptively simple on paper. One covalent bond. Four atoms in a flat plane. And yet it is the structural backbone of hormones, signalling molecules, enzymes, and the increasingly scrutinised class of compounds researchers call peptides. Without it, none of those molecules exist.

What a peptide bond actually is

A peptide bond forms when the carboxyl group (–COOH) of one amino acid reacts with the amino group (–NH₂) of another. A water molecule is released , hence "condensation reaction" , and what remains is a –CO–NH– linkage between the two residues. That's it. The new molecule is called a dipeptide.

Chain three amino acids together and you have a tripeptide. Keep going past roughly 50 residues and convention shifts to "polypeptide" or "protein," though the boundary is fuzzy and biochemists argue about it more than you'd expect at conferences.

The bond itself has a partial double-bond character, because the lone pair of electrons on the nitrogen delocalises into the adjacent carbonyl. This is not a minor detail. It means the four atoms; C, O, N, H, are locked into the same plane and rotation around the bond is heavily restricted. That planarity is what forces polypeptide chains into the predictable secondary structures we call alpha-helices and beta-sheets. Shape, in biology, is function. The rigidity of the peptide bond is where that shape starts.

How the bond forms in living cells

Inside a cell, peptide bonds don't assemble spontaneously, the reaction is thermodynamically unfavourable in aqueous solution without an energy input. Ribosomes handle this using aminoacyl-tRNA molecules, which carry activated amino acids, and the energy stored in those high-energy ester bonds drives the condensation forward. The ribosome's peptidyl transferase centre catalyses the reaction, and the growing polypeptide chain is extended one residue at a time, from N-terminus to C-terminus.

Chemists working in the lab reproduce this using solid-phase peptide synthesis (SPPS), developed by Robert Bruce Merrifield in the 1960s; work that earned him a Nobel Prize in Chemistry in 1984. SPPS anchors the growing chain to a resin support and adds protected amino acids sequentially, deprotecting each one before coupling the next. It's elegant, and it's the reason synthetic peptides are now accessible as research compounds at all.

Why the bond's stability matters for pharmacokinetics

Here's where things get interesting from a pharmacokinetics perspective. Peptide bonds are stable in neutral conditions, but the human body is full of enzymes called proteases, and proteases are extremely good at breaking them. Stomach acid and gastrointestinal proteases like pepsin, trypsin, and chymotrypsin will degrade most unmodified peptides before they reach systemic circulation. This is why oral bioavailability is a persistent challenge for peptide-based compounds.

It's also a big part of why subcutaneous injection is the standard delivery route for many peptide compounds in research and clinical contexts, it bypasses the GI tract and avoids the first-pass metabolism that would otherwise shred the molecule before it ever reached its target. The bioavailability picture changes substantially the moment you change the route.

Researchers have developed several strategies to improve peptide stability: cyclisation (forming a ring structure that removes the vulnerable termini), N-methylation of backbone amides (which blocks the protease's usual approach), incorporation of D-amino acids (proteases evolved to cleave L-amino acid bonds), and PEGylation (attaching polyethylene glycol chains to slow renal clearance). Each modification changes the molecule's behaviour profile; sometimes usefully, sometimes with unintended consequences on receptor selectivity.

Peptide bonds in endogenous signalling molecules

The body already uses peptide bonds extensively for chemical signalling. Neuropeptides like oxytocin (nine amino acid residues) and vasopressin (also nine residues, differing by just two) are small, tightly structured molecules whose precise conformation, determined by those constrained peptide bonds and a disulfide bridge, governs receptor binding specificity. Get the shape slightly wrong and the molecule either loses affinity or hits an off-target receptor.

The GLP-1 receptor agonist class is a more recently prominent example. GLP-1 itself is a 30-amino-acid peptide; the synthetic analogue compounds used clinically are modified versions engineered for resistance to the enzyme dipeptidyl peptidase-4 (DPP-4), which would otherwise cleave the natural molecule within minutes. The modifications protect specific peptide bonds without disrupting the receptor-binding surface. For a detailed look at that receptor class, the GLP-1 receptor agonist glossary entry covers the classification.

There's a conceptual parallel worth noting with the endocannabinoid system, too. Endocannabinoids like anandamide aren't peptides; they're lipid-derived, but the same principle applies: endogenous signalling molecules are built with structural precision, and that precision is what enables selective receptor engagement. The peptide bond is the architectural tool biology uses for one large branch of that signalling tree.

The regulatory picture for synthetic peptides in Australia

I'll be direct here, because this area causes a lot of confusion. Many synthetic peptides marketed in Australia as performance or research compounds have not been evaluated for safety and efficacy by the Therapeutic Goods Administration (TGA) and are not entered on the Australian Register of Therapeutic Goods (ARTG). Supplying such products without the relevant approval is illegal under the Therapeutic Goods Act 1989. The TGA has been actively enforcing this, including issuing warning letters and undertaking prosecutions; and the regulatory pressure has intensified since 2021.

Peptide compounds that do have clinical use are generally accessed via prescription pathways. Where they hold Schedule 4 (Prescription Only) or Schedule 8 (Controlled Drug) status under the Poisons Standard, supply requires a valid prescription from a registered Australian medical practitioner. Some investigational compounds may be accessible through the Special Access Scheme or via an Authorised Prescriber arrangement, but these pathways involve significant regulatory obligations and are not a general access route for consumers.

Honestly, I think the discourse around synthetic peptides online has run well ahead of both the evidence base and the regulatory framework. That's worth saying plainly.

Reading the structure: what the bond tells you

One thing I find underappreciated in popular-level peptide writing is that understanding the bond gives you real interpretive power. When you look at a peptide's sequence notation, say, H-Ala-Gly-Pro-OH, you're reading a list of residues connected by peptide bonds, from the free amino terminus (H-) to the free carboxyl terminus (-OH). Proline is notable because its side chain loops back to form a bond with the backbone nitrogen, constraining the preceding peptide bond and introducing kinks that disrupt standard secondary structures. It's why proline is sometimes called a "helix breaker"; the geometry enforced by the nitrogen's cyclic structure physically cannot accommodate a standard alpha-helical hydrogen bond at that position.

These structural features cascade into how a molecule behaves in solution, how it folds, and ultimately how it interacts with a receptor. The peptide bond is the foundational unit of all of that. Everything upstream depends on it.

If this is your entry point into peptide science, the amino acid and peptide glossary entries are the natural next stops. And if you're thinking about how peptide stability interacts with different delivery routes and absorption, the pharmacokinetics overview will give that context.

Sources

, Priya Nandakumar, Pharmacology writer, peptides & PK

]]>

Common questions

What is a peptide bond in simple terms?: A peptide bond is a covalent chemical link formed when the carboxyl group of one amino acid reacts with the amino group of another, releasing a water molecule. It's the bond that joins amino acids into chains to form peptides and proteins.
Why are peptide bonds hard to deliver orally?: Proteases in the stomach and small intestine break peptide bonds efficiently, degrading most unmodified peptide compounds before they reach systemic circulation. This severely limits oral bioavailability, which is why many peptide compounds in research contexts are administered by subcutaneous injection instead.
What is the difference between a peptide and a protein?: Both are chains of amino acids linked by peptide bonds. The distinction is largely one of length — peptides are generally considered to be chains of fewer than roughly 50 amino acid residues, while proteins are longer. The boundary is not fixed and the terminology overlaps in practice.
Are synthetic peptides legal in Australia?: It depends entirely on the specific compound and its regulatory status. Peptide therapeutic goods must be entered on the Australian Register of Therapeutic Goods (ARTG) to be legally supplied. Many synthetic peptides marketed online are unapproved, and supplying them is illegal under the Therapeutic Goods Act 1989. Some clinically recognised peptide compounds may be available via prescription or the Special Access Scheme. The TGA is the authoritative source on any specific compound's status.
What makes proline unusual in a peptide chain?: Proline's side chain forms a ring that bonds back to the backbone nitrogen, which restricts rotation around the preceding peptide bond and prevents standard hydrogen bonding. This disrupts the formation of alpha-helices and beta-sheets at that position, giving proline the ability to introduce structural kinks or turns in a peptide chain.